loss

American Financial Group, Inc. Announces Second Quarter Results

Net earnings per share of $2.07; includes $0.07 per share loss from non-core items Second quarter core net operating earnings…

1 week ago

TrimIQ Weight Loss: Official launched in UK and Ireland With Green Tea Probiotic Complex

New York City, NY, Aug. 02, 2025 (GLOBE NEWSWIRE) -- TrimIQ UK, a pioneering health and wellness brand, proudly announces…

2 weeks ago

PMI Calls for Ongoing G2G Dialogues with Source and Transit Countries to Combat Illicit Tobacco Trade

- India faces an annual loss of approximately $1.65 billion, with 25% of the domestic market illicit and an estimated…

2 weeks ago

Pink Salt Trick Recipe to Weight Loss Trend 2025: An Analysis of Slumber Slim as a Science Informed Option

Albany, New York, July 26, 2025 (GLOBE NEWSWIRE) -- An internet-viral pink salt recipe has swept the TikTok platform purporting…

3 weeks ago

Justice4Heroes Campaign Demands Equality in Military Hearing Loss Compensation

Monday 21 July, 2025 PRESS RELEASE FOR IMMEDIATE RELEASE Justice4Heroes Campaign Demands Equality in Military Hearing Loss Compensation UK –…

3 weeks ago

Safest SARMs For Muscle Growth 2025: CrazyBulk IntroducesEffectiveSARMs For Bulking, Cutting and Strength in USA.

Albany, New York, July 15, 2025 (GLOBE NEWSWIRE) -- In the ever-evolving world of fitness and bodybuilding, achieving optimal muscle…

1 month ago

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine

Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed mean weight reduction in the highest range of…

2 months ago

Novo Nordisk: Higher dose of Wegovy provided average weight loss of 21% in people with obesity with a third achieving 25% or more according to data presented at ADA

Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25%…

2 months ago

Novo Nordisks subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025

Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people with overweight or obesity was…

2 months ago

New Survey Finds Younger Adults, More Women Seeking Treatment for Hair Loss

Manageable number of monthly hair restoration surgeries illustrates ISHRS members' hands-on, expert approach CHICAGO, June 10, 2025 /PRNewswire/ -- According to results…

2 months ago